Oruka Therapeutics (ORKA) Net Cash Flow (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Net Cash Flow of $2.6 million for Q1 2026, down 88.25% year-over-year from $22.0 million in Q1 2025, and up 105.83% quarter-over-quarter from -$44.3 million in Q4 2025.
Oruka Therapeutics (ORKA) Net Cash Flow (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 88.25% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at -$34.2 million (down 161.19% YoY), while the FY2025 annual figure was -$14.6 million, down 123.78% from the prior year.
- Net Cash Flow for Q1 2026 stood at $2.6 million, up from -$44.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $395.8 million in Q3 2024, with the low at -$349.3 million in Q4 2024.
- The 5-year median for Net Cash Flow is -$1.6 million (2023), against an average of $2.0 million.
- Peak annual rise in Net Cash Flow reached 23812.04% in 2024, while the deepest fall reached 32977.65% in 2024.
- Oruka Therapeutics' Net Cash Flow stood at -$1.5 million in 2022, then rose by 29.32% to -$1.1 million in 2023, then slumped by 32977.65% to -$349.3 million in 2024, then jumped by 87.31% to -$44.3 million in 2025, then jumped by 105.83% to $2.6 million in 2026.
- Business Quant data shows ORKA's Net Cash Flow at $2.6 million in Q1 2026, -$44.3 million in Q4 2025, and $25.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | 218.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 218.95 Mn |
| Jun 30, 2026 | 218.95 Mn |
| Mar 31, 2026 | 2.59 Mn |
| Mar 31, 2026 | 2.59 Mn |
| Dec 31, 2025 | -44.33 Mn |
| Dec 31, 2025 | -44.33 Mn |
| Sep 30, 2025 | 25.87 Mn |
| Sep 30, 2025 | 25.87 Mn |
| Jun 30, 2025 | -18.29 Mn |
| Jun 30, 2025 | -18.29 Mn |
| Mar 31, 2025 | 22.00 Mn |
| Mar 31, 2025 | 22.00 Mn |
| Dec 31, 2024 | -349.30 Mn |
| Dec 31, 2024 | -349.30 Mn |
| Sep 30, 2024 | 395.75 Mn |
| Sep 30, 2024 | 395.75 Mn |
| Jun 30, 2024 | -12.62 Mn |
| Jun 30, 2024 | -12.62 Mn |
| Mar 31, 2024 | 27.74 Mn |
| Mar 31, 2024 | 27.74 Mn |